Denali Therapeutics (DNLI) Releases Earnings Results, Beats Expectations By $0.90 EPS

Denali Therapeutics (NASDAQ:DNLI) posted its earnings results on Tuesday. The company reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.90, MarketWatch Earnings reports. The firm had revenue of $125.68 million for the quarter, compared to analyst estimates of $9.73 million.

Shares of NASDAQ DNLI traded up $2.35 during mid-day trading on Wednesday, reaching $24.55. The company had a trading volume of 559,023 shares, compared to its average volume of 321,004. Denali Therapeutics has a one year low of $12.32 and a one year high of $23.28. The stock has a market capitalization of $1.97 billion, a P/E ratio of -4.17 and a beta of 2.08.

A number of equities research analysts have recently weighed in on DNLI shares. ValuEngine downgraded Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 29th. Cantor Fitzgerald cut Denali Therapeutics from an “overweight” rating to a “neutral” rating and set a $25.00 price target on the stock. in a research report on Tuesday, January 29th. Finally, Zacks Investment Research upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a research report on Thursday, January 3rd.



In related news, COO Alexander O. Schuth sold 7,500 shares of the firm’s stock in a transaction on Tuesday, February 12th. The stock was sold at an average price of $19.08, for a total value of $143,100.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Ryan J. Watts sold 18,333 shares of the firm’s stock in a transaction on Friday, January 4th. The stock was sold at an average price of $19.43, for a total value of $356,210.19. The disclosure for this sale can be found here. Insiders sold 70,000 shares of company stock worth $1,401,924 in the last 90 days. 21.30% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: This news story was reported by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this news story on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this news story can be accessed at https://dakotafinancialnews.com/2019/03/13/denali-therapeutics-dnli-releases-earnings-results-beats-expectations-by-0-90-eps.html.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Read More: Google Finance Portfolio Tips and Tricks

Earnings History for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.